168 related articles for article (PubMed ID: 35574304)
1. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon
Yang JC; Schuler M; Popat S; Miura S; Park K; Passaro A; De Marinis F; Solca F; Märten A; Kim ES
Front Oncol; 2022; 12():834704. PubMed ID: 35574304
[TBL] [Abstract][Full Text] [Related]
2. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S
Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704
[TBL] [Abstract][Full Text] [Related]
4. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
5. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
[TBL] [Abstract][Full Text] [Related]
6. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Passaro A; de Marinis F; Tu HY; Laktionov KK; Feng J; Poltoratskiy A; Zhao J; Tan EH; Gottfried M; Lee V; Kowalski D; Yang CT; Srinivasa BJ; Clementi L; Jalikop T; Huang DCL; Cseh A; Park K; Wu YL
Front Oncol; 2021; 11():709877. PubMed ID: 34307179
[TBL] [Abstract][Full Text] [Related]
7. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M; Parikh K; Banna GL; Kim F; Olivier T; Le X; Addeo A
J Thorac Oncol; 2024 Mar; ():. PubMed ID: 38499147
[TBL] [Abstract][Full Text] [Related]
9. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
[TBL] [Abstract][Full Text] [Related]
10. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
Ullas B; Shrinidhi N; Mansi S; Narayan S; Parveen J; Surender D; Joslia JT; Anurag M
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1541-1549. PubMed ID: 35581383
[TBL] [Abstract][Full Text] [Related]
11. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
[TBL] [Abstract][Full Text] [Related]
12. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
[TBL] [Abstract][Full Text] [Related]
13. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib in non-small cell lung cancer with uncommon
Eide IJZ; Stensgaard S; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Sørensen BS; Brustugun OT
Transl Lung Cancer Res; 2022 Jun; 11(6):953-963. PubMed ID: 35832438
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
[TBL] [Abstract][Full Text] [Related]
16. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
Li T; Wang S; Ying J; Wang Y; Hu X; Hao X; Xu Z; Xing P; Li J
Thorac Cancer; 2021 Nov; 12(21):2924-2932. PubMed ID: 34549528
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
Masood A; Kancha RK; Subramanian J
Semin Oncol; 2019 Jun; 46(3):271-283. PubMed ID: 31558282
[TBL] [Abstract][Full Text] [Related]
20. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
